Drug Trial Radar · NCT04988035
ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19
Last checked: Nov 20, 2026Latest source record: Jun 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
201
Actual
Start
Aug 3, 2021
Primary completion
Apr 23, 2022
Study completion Apr 23, 2022
Sponsor
- Sponsor type
- NIH
- First posted
- Aug 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a platform trial to conduct a series of randomized, double-blind, placebo-controlled trials using common assessments and endpoints in hospitalized adults diagnosed with COVID-19. BET is a proof-of-concept study with the intent of identifying promising treatments to enter a more definitive study. The study will be conducted in up to 70 domestic sites and 5 international sites. The study will compare different investigational therapeutic agents to a common control arm and determine which have relatively large effects. In order to maintain the double blind, each intervention will have a matched placebo. However, the control arm will be shared between interventions and may include participants receiving the matched placebo for a different intervention. The goal is not to determine clear statistical significance for an intervention, but rather to determine which products have clinical data suggestive of efficacy and should be moved quickly into larger studies. Estimates produced from BET will provide an improved basis for designing the larger trial, in terms of sample size and endpoint selection. Products with little indication of efficacy will be dropped on the basis of interim evaluations. In addition, some interventions may be discontinued on the basis of interim futility or efficacy analyses. One or more interventions may be started at any time. The number of interventions enrolling are programmatic decisions and will be based on the number of sites and the pace of enrollment. At the time of enrollment, subjects will be randomized to receive any one of the active arms they are eligible for or placebo. Approximately 200 (100 treatment and 100 shared placebo) subjects will be assigned to each arm entering the platform and a given site will generally have no more than 3 interventions at once. The BET-C stage will evaluate the combination of remdesivir with danicopan vs remdesivir with a placebo. Subjects will be assessed daily while hospitalized. Once subjects are discharged from the hospital, they will have a study visit at Days 8, 15, 22, 29, and 60 as an outpatient. The Day 8, Day 22 and Day 60 visits do not have laboratory tests or collection of samples and may be conducted by phone. All subjects will undergo a series of efficacy and safety laboratory assessments. Safety laboratory tests and blood (serum, plasma and RNA) research samples on Day 1 (prior to study product administration) and Days 3, 5, 8, and 11 while hospitalized. Blood research samples plus safety laboratory tests will be collected on Day 15 and 29 if the subject attends an in-person visit or is still hospitalized. However, if infection control considerations or other restrictions prevent the subject from returning to the clinic, Day 15 and 29 visits may be conducted by phone and only clinical data will be obtained. The primary objective is to evaluate the clinical efficacy of danicopan relative to the control arm in adults hospitalized with COVID-19 according to clinical status (8-point ordinal scale) at Day 8.
Conditions
- COVID-19
Interventions
DanicopanDrug
Danicopan is a small molecule, orally administered complement factor D (FD) inhibitor
PlaceboOther
Danicopan matching placebo tablet
RemdesivirDrug
Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Meeting Criteria for Each of the 8 Ordinal Scale Categories on Day 8Time frame: Day 8
Locations
39 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham School of Medicine - Infectious Disease
Birmingham, Alabama
Kern Medical Center
Bakersfield, California
UCSF Fresno Center for Medical Education and Research - Clinical Research Center
Fresno, California
University of California Los Angeles Medical Center - Westwood Clinic
Los Angeles, California
Hoag Hospital Newport Beach
Newport Beach, California
Penrose Hospital - Emergency Medicine
Colorado Springs, Colorado
St. Francis Medical Center
Colorado Springs, Colorado
St. Anthony Hospital
Lakewood, Colorado
St. Anthony Hospital North Health Campus
Westminster, Colorado
Nuvance Health Danbury Hospital - Infectious Disease
Danbury, Connecticut
Yale School of Medicine - The Anlyan Center for Medical Research & Education - Immunobiology
New Haven, Connecticut
Nuvance Health - Norwalk Hospital - Asthma Pulmonary and Critical Care Medicine
Norwalk, Connecticut
University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine
Gainesville, Florida
Mayo Clinic Florida
Jacksonville, Florida
Great Lakes Clinical Trials
Chicago, Illinois
Carle Foundation Hospital
Urbana, Illinois
Northwestern Medicine - Central DuPage Hospital - Infectious Disease
Winfield, Illinois
Norton Healthcare
Louisville, Kentucky
University of Louisville - Division of Infectious Diseases
Louisville, Kentucky
Brigham and Women's Hospital - Infectious Diseases
Boston, Massachusetts
William Beaumont Hospital - Royal Oak Campus - Infectious Disease
Royal Oak, Michigan
Hennepin Healthcare Research Institute
Minneapolis, Minnesota
Mayo Clinic, Rochester - Infectious Diseases
Rochester, Minnesota
University of Nebraska Medical Center - Infectious Diseases
Omaha, Nebraska
The State University of New York - University at Buffalo - Department of Medicine
Buffalo, New York
Mount Sinai School of Medicine - Medicine - Infectious Diseases
New York, New York
Nuvance Health - Vassar Brothers Medical Center
Poughkeepsie, New York
Stony Brook Medicine - Stony Brook University Hospita
Stony Brook, New York
Jacobi Medical Center
The Bronx, New York
Montefiore Medical Center - Infectious Diseases
The Bronx, New York
Wake Forest Baptist Health - Infectious Diseases
Winston-Salem, North Carolina
St. Charles Health System - St. Charles Bend Hospital
Bend, Oregon
Doylestown Hospital
Doylestown, Pennsylvania
Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases
Hershey, Pennsylvania
Kent County Memorial Hospital
Warwick, Rhode Island
Hendrick Health - Hendrick Medical Center
Abilene, Texas
Baylor Scott & White Health - Baylor University Medical Center - North Texas Infectious Disease Consultants
Dallas, Texas
University of Utah - Infectious Diseases
Salt Lake City, Utah
West Virginia University - Infectious Diseases Clinic
Morgantown, West Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.